1. Home
  2. Live Updates
  3. Division of hematology

Live Breaking News & Updates on Division of hematology

Stay informed with the latest breaking news from Division of hematology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Division of hematology and stay connected to the pulse of your community

Gut Bacteria Enzyme Converts Blood to Universally Compatible Blood Group

The findings from a new research study published in <i>Nature</i> could help boost blood transfusion stocks by offering a novel way to convert blood cells from one group to another.

Denmark , United-kingdom , Martinl-olsson , Division-of-hematology , Technology-network , Transfusion-medicine-at-lund-university , Department-of-biotechnology , Technical-university-of-denmark , American-red-cross , Maher-abou-hachem , Technical-university , Transfusion-medicine

Dr Binod Dhakal Discusses Game-Changing Cilta-Cel Approval for RRMM

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, drom which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.

Janssen-johnson-carvykti , Binod-dhakal , College-of-wisconsin , Division-of-hematology , Medical-college , Cilta-cel , Carvykti , Ciltacabtagene-autoleucel- , Cartitude-4- ,

Drug targeting clear cell renal cell carcinoma shows promising approach

In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively di

Texas , United-states , Dallas , Robert-lewis-kirby , Nizarm-tannir , James-brugarolas , Division-of-hematology , Sherry-wigley-crow-cancer-research , Simmons-cancer-center , Southwestern-medical-center , Kidney-cancer-program , Arrowhead-pharmaceuticals

Six from Penn elected 2024 AAAS Fellows

Six from Penn elected 2024 AAAS Fellows
upenn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upenn.edu Daily Mail and Mail on Sunday newspapers.

Philadelphia , Pennsylvania , United-states , Wharton-school , University-of-pennsylvania , Shu-yang , Fujian , China , Applied-science , Chinese , American , Tony-cai

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Tisagenlecleucel-kymriah , Rahul-banerjee , Division-of-hematology , University-of-washington , Clinical-research-division , Fred-hutchinson-cancer-center , Adverse-event-reporting-system , Event-reporting-system ,

Dr Grivas on Frontline Treatment Options in Metastatic RCC

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Petros-grivas , Scott-tykodi , University-of-washington-uw-school-medicine , Fred-hutchinson-cancer-center , Clinical-research-division , Division-of-hematology , Genitourinary-cancers-program , Science-summit , D , Hd , Patients-with-metastatic-renal-cell-carcinoma ,

Dr Gangat on the Evolution of JAK Inhibitors in Myelofibrosis

Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.

Ruxolitinib-jakafi , Naseema-gangat , Department-of-medicine , Division-of-hematology , Mayo-clinic-rochester , Myelofibrosis , Jak-inhibitors ,

Dr Sekeres on Using MDS Risk-Stratification Systems in Clinical Practice

Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.

Mikkaela-sekeres , Division-of-hematology , Sylvester-comprehensive-cancer-center , University-of-miami-health-system , Leukemia-section , Miami-health-system , Science-summit ,

Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Bhagirathbhai-dholaria , Division-of-hematology , Vanderbilt-university-medical-center ,

Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Phoenix , Arizona , California , Chicago , Illinois , University-of-minnesota , Minnesota , Orange-county , Los-angeles , Ilanit-allen , Myron-czuczman